Drawing for KANGAROO ISLAND NATURALS

USPTO serial 79134622

KANGAROO ISLAND NATURALS

Reviewed by CopyMark Law Group

Reg. 4697591Status 404
Filing date
Status date
Registration date
Mar 10, 2015
Examiner
MCCAULEY, BRENDAN D
Law office
GENERIC WEB UPDATE

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with KANGAROO ISLAND NATURALS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Howard A. MacCord, Jr.

Howard A. MacCord, Jr. MACCORD MASON PLLC2733 Horse Pen Creek Road, Suite 101GREENSBORO, NC 27410UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
003[ Cosmetics being anti-sun preparations, namely, cosmetic preparations for protecting the skin from the sun's rays, cosmetic sun-protecting preparations and non-medicated sun care preparations; ] Cosmetics, namely, body creams; [ cleaning oils for cosmetic purposes; cosmetic acne cleansers, namely, facial cleaning preparation in the nature of salicylic acne cleanser not for medical purposes and non-medicated acne treatment preparations; cosmetic bath products, namely, bath lotions, bath gels and bubble bath; cosmetic cotton wool; cosmetic preparations for cleansing the mouth, namely, mouth washes and non-medicated mouth rinse; cosmetics; cosmetics for animals; cosmetics for protecting the skin from sunburn; ] cosmetics for the treatment of dry skin; cosmetics for the use on the hair; cosmetics for use on the skin; cosmetics preparations; [ cotton pads for cosmetic use; facial wipes impregnated with cosmetics; hair cosmetics; ] cosmetics, namely, moisturizers; [ cosmetics, namely, nail preparation; ] cosmetic nourishing creams; [ cosmetic oils for the skin; non-medicated cosmetic skin balms; ] cosmetics, namely, non-medicated skin care creams; cosmetics, namely, non-mediates skin care lotions; [ cosmetic skin care oils, namely, body oil and face oil; ] cosmetics, namely, non-medicated skin care preparations; cosmetic skin care products, namely, cosmetic creams for skin care, cosmetic preparations for skin care and non-medicated skin serum; non-medicated cosmetic skin cleansing preparations [ ; cosmetics being sun barriers, namely, sun block; cosmetics, namely, sun blocking preparations; cosmetics being sun protection products, namely, sun screen and sun screen preparations; cosmetic sun skin care products, namely, after sun creams, gels and lotions ]SECTION 70 - CANCELLED—
005[ Pharmaceutical preparations in the nature of acne cleansers for the treatment of acne, anti-bacterials, antifungals, antiviruses and anti-septics for the treatment of skin and soft tissue infections, scalp infections and disorder conditions, oral and dental infections, eye and ear infections, respiratory tract infections, gastro-intestinal tract infections, cardiovascular system infections, systemic infections, urinal tract infections and bacterial vaginosis; Pharmaceutical preparations for the treatment of skin and soft tissue infections, namely, leprosy, carbuncles, staph infections, erysipelas, cellulitis, necrotizing fasciitis, boils, pilonidal cysts and abscesses, impetigo, eczema, psoriasis, seborrheic dermatitis, acne and pimples, wound infections, minor burns, skin ulcers and abrasions, infection of fingernails, toenails and nail beds, ingrown nails, athlete's foot, jock itch, ringworm, yeast infections, cutaneous candidiasis, tinea versicolour, sporotrichosis, molluscum contagiosum, shingles, chickenpox and herpes stomatitis; Pharmaceutical preparations for the treatment of skin disorders, namely, wrinkles, freckles, melasma, varicose veins, flaking skin, eczema, acne, psoriasis, stretch marks, severe dry skin, cracked skin, itching, scaling and scars, skin aging, burns, wound ulcers, seborrhoeic keratoses, warts, pemphigoid, actinic keratosis, lupus, dermatomyositis, vitiligo, keloid, ichthyosis vulgaris, molluscum contagiosum, shingles, chickenpox, herpes stomatitis and vaginal atrophy; Pharmaceutical preparations for the treatment of scalp infections and disorder conditions, namely, dandruff, inflammatory hair loss and folliculitis; Pharmaceutical preparations for the treatment of oral and dental infections, namely, mouth gum and throat infections, mouth ulcers, mouth deodorant and cold sores; Pharmaceutical preparations for the treatment of allergies, namely, hives, lichen planus, insect bites and stings, skin allergies, skin rashes, nappy rash, heat rash and sweat rash; Pharmaceutical preparations for the treatment of sun damage, namely, sun burn, rosacea, solar keratoses, sun spots, skin lesions and melanoma; Pharmaceutical preparations for the treatment of pain and inflammation, muscle, joint and bone disorders, cardiovascular diseases, hyperlipidemia, peripheral circulatory disorders, diabetic and metabolic disorders; Pharmaceutical preparations for health care, namely, antimicrobials, namely, Amoxicillin, Cephalexin, Mupirocin, and Chloramphenicol; antifungal pharmaceutical products, namely, Clotrimazole, Fluconazole, and Terbinafine; anti-yeast pharmaceutical products, namely, Nystatin, and Clotrimazole; antivirus pharmaceutical products, namely, Aciclovir, Famciclovir, and Oseltamivir; anti-septic pharmaceutical products, namely, Cetrimide, Chlorhexidine, and tea tree oil for medical purposes; anti-aging pharmaceutical products, namely, Vitamin A, Vitamin C, Alpha Hydroxy acids, Retinol, Collagen, Elastin, and Resveratrol; anti-oxidant pharmaceutical products, namely, Vitamin E, Lycopene, Resveratrol, and Coenzyme Q10; analgesic and anti-inflammation pharmaceutical products, namely, Aspirin, Ibuprofen, Paracetamol, Celecoxib, Meloxicam, and Corticosteroid; anti-sun care pharmaceutical products, namely, Tretinoin, Avobenzone, Butyl methoxydibenzoylmethane, Homosalate, Octinoxate, Octisalate, Octocrylene, Oxybenzone, Titanium dioxide, and Zinc Oxide; after sun care pharmaceutical products, namely, aloe vera for therapeutic purposes, Vitamin B5, Vitamin C, Vitamin E, and petroleum jelly for medical purposes; skin lesion care pharmaceutical products, namely, Fluorouracil, and Imiquimod; skin and body care pharmaceutical products, namely, Tretinoin, Calcipotriol, Coal tar for medical purposes, Benzoyl peroxide, Resorcinol, Salicylic acid, Hydrocortisone, Methylprednisolone, Triamcinolone, Betamethasone, Cetrimide, Chlorhexidine, Vitamin B5, Vitamin C, Vitamin E, Urea, and petroleum jelly for medical purposes; face care pharmaceutical products, namely, Isotretinoin, Benzoyl peroxide, Resorcinol, and Salicylic acid; nail care pharmaceutical products, namely, Amorolfine, Ciclopirox, Clotrimazole, and Terbinafine; burn and wound care pharmaceutical products, namely, Tea tree oil for medical purposes, Medihoney, and Silver sulfadiazine; peripheral circulatory care pharmaceutical products, namely, Chilblain cream, and Gingko biloba tablets for medical purposes; muscle, joint and bone care pharmaceutical products, namely, fish oil for medical purposes, krill oil for medical purposes, Glucosamine and Chondroitin, and Vitamin D; health tonic pharmaceutical products, namely, panax ginseng tablets for medical purposes and ginger tablets for medical purposes; hair and scalp care pharmaceutical products, namely, coal tar for medical purposes, Pinetar for medical purposes, Ciclopirox, Ketoconazole, Mometasone furoate, Piroctone olamine, Salicylic acid, Selenium, Vitamin E, and Zinc pyrithione; cardiovascular protection pharmaceutical products, namely, Aspirin, Atorvastatin, Simvastatin, Rosuvastatin, Resveratrol, and Coenzyme Q10; anti-lipidemia pharmaceutical products, namely, Atorvastatin, Simvastatin, Rosuvastatin, and Fenofibrate; diabetic type 2 care pharmaceutical products, namely, Metformin, Gliclazide, and Resveratrol; anti-allergy pharmaceutical products, namely, Fexofenadine, Cetirizine, Levocetirizine, Betamethasone, Hydrocortisone, Mometasone furoate, Methylprednisolone, and Triamcinolone; insect bites and sting pharmaceutical products, namely, Aluminium sulfate, Cetrimide, Chlorhexidine, and tea tree oil for medical purposes; modulation of immunity pharmaceutical products, namely, Corticosteroid, Cyclosporine, Azathioprine, and Leflunomide; respiratory care pharmaceutical products, namely, Bromhexine, Ipratropium, Salbutamol, Corticosteroid, Tiotropium, and Montelukast; gastro-intestinal tract care pharmaceutical products, namely, Hyoscine butylbromide, Esomeprazole, Omeprazole, and Pantoprazole; Pharmaceutical preparations in the form of lotions, namely, pharmaceutical skin lotions, pharmaceutical preparations in the form of lozenges, namely, medicated lozenges and throat lozenges, pharmaceutical preparations in the form of tablets, namely, allergy tablets and antibiotic tablets; Pharmaceutical moisturizing preparations, namely, medicated skin moisturizers, for use on the skin for the treatment of wrinkles, freckles, melasma, varicose vein, flaking skin, eczema, acne, psoriasis, stretch marks, severe dry skin, cracked skin, itching, scaling and scars, skin aging, burns, wound ulcers, seborrhoeic keratoses, warts, pemphigoid, actinic keratosis, lupus, dermatomyositis, vitiligo, keloid, ichthyosis vulgaris, molluscum contagiosum, shingles, chickenpox, herpes stomatitis, insect bites and stings, skin allergies, hives, lichen planus, skin rashes, nappy rash, heat rash, sweat rash, vaginal atrophy, rosacea, sun damage, sun burn, solar keratoses, sun spots, skin lesion and melanoma; Pharmaceutical preparations for use in the treatment of skin blemishes, in the nature of acne cleansers, namely, liver spots, purpura, seborrheic keratoses, acne, pimples, skin disclouration, dark spots, red spots, white heads, black heads, papules, pustule, rosacea, cystic acne, nodules, sun damaged skin and aging skin; Pharmaceutical preparations for application to the scalp for the treatment of inflammatory hair loss, Tinea capitis, trichotillomania, alopecia areata, seborrheic eczema, dermatitis, cradle cap, psoriasis, dandruff or pityriasis capitis, pityriasis amiantacea, lichen simplex, folliculitis, scalp infection, hair loss, baldness, hair thinning conditions and hair shaft abnormalities; Pharmaceutical preparations for application to the nails for the treatment of eczema, dermatitis and psoriasis of the nail fold, paronychia, fungal infection, onychomycosis, tinea, and athlete's foot, inflammation of the nail fold, nail discoloration and nail thickening; Pharmaceutical preparations for skin care and topical use, namely, Mupirocin, Polymyxin B, Neomycin, Bacitracin, Terbinafine, Clotrimazole, Nystatin, Aciclovir, Penciclovir, Amorolfine, Ciclopirox, Itraconazole, Fluconazole, Ketoconazole, Hydrocortisone, Methylprednisolone, Triamcinolone, Betamethasone, Mometasone furoate, Isotretinoin, Calcipotriol, Coal tar for medical purposes, Pinetar for medical purposes, Piroctone olamine, Benzoyl peroxide, Resorcinol, Salicylic acid, Selenium, Zinc pyrithione, Silver sulfadiazine, Chilblain cream, Aluminium sulfate, Tea tree oil for medical purposes, Cetrimide, Chlorhexidine, Vitamin B5, Vitamin C, Vitamin E, Urea, Petroleum for medical purposes, Tretinoin, Avobenzone, Butyl methoxydibenzoylmethane, Homosalate, Octinoxate, Octisalate, Octocrylene, Oxybenzone, Titanium dioxide, Zinc Oxide, Fluorouracil and Imiquimod; Pharmaceutical preparations for animals for the treatment of skin and soft tissue infections, oral and dental infections, eye and ear infections, respiratory tract infections, gastro-intestinal tract infections, urinary tract infections, cardiovascular system infections, systemic infections, severe sepsis, wound ulcers, burns, skin lesions, melanoma, pain and inflammation, cardiovascular diseases, hyperlipidemia, peripheral circulatory disorders, muscle, joint and bone disorders, and diabetic and metabolic disorders; Pharmaceutical preparations for veterinary use, namely, parasiticides and dermatological preparations, namely, Azoles, Fipronil, Imidacloprid, Ivermectin, and Pyrantel; antibiotics pharmaceutical products, namely, Amoxicillin, and Cephalexin; immunotherapy pharmaceutical products, namely, Cyclosporin, and Corticosteroids; nutrition and metabolism pharmaceutical products, namely, Omega-3, and fish oil for medical purposes; musculosketal system pharmaceutical products, namely, Firocoxib, Meloxicam, and fish oil for medical purposes; pain and inflammation pharmaceutical products, namely, Aspirin, Ibuprofen, Firocoxib, Meloxicam, and Naproxen; allergy pharmaceutical products, namely, Clemastine, Chlorpheniramine, Hydroxyzine, Fexofenadine, Cetirizine, and Prednisone; cardiovascular protection pharmaceutical products, namely, Aspirin, and Moxidectin; respiratory pharmaceutical products, namely, Bromhexine, Albuterol, and Corticosteroids; gastro-intestinal tract pharmaceutical products, namely, Hyoscine butylbromide; ] Propolis for pharmaceutical purposes, namely, propolis for medicinal or therapeutic purposes, namely, propolis cream [, propolis lotion, propolis liquid, propolis lozenges and propolis softgel capsules, to treat skin and soft tissue infections and disorder conditions, nail infections and disorder conditions, scalp infections and disorder conditions, oral and dental infections, eye and ear infections, respiratory tract infections, gastro-intestinal tract infections, cardiovascular system infections, systemic infections, urinal tract infections, bacterial vaginosis, itching, allergies, insect bites and stings, rashes, sun burns, rosacea, solar keratoses, skin lesions, melanoma, pain and inflammation, muscle, joint and bone disorders, cardiovascular diseases, hyperlipidemia, peripheral circulatory disorders and diabetic and metabolic disorders; Plant extracts for pharmaceutical use, namely, plant extracts for pharmaceutical purposes, namely, Gingko biloba for medical purposes, Ginger and Panax ginseng for medical purposes, to treat skin and soft tissue infections and disorder conditions, nail infections and disorder conditions, scalp infection and disorder conditions, oral and dental infections, eye and ear infections, respiratory tract infections, gastro-intestinal tract infections, cardiovascular system infections, systemic infections, urinal tract infections, bacterial vaginosis, itching, allergies, insect bites and stings, rashes, sun burn, rosacea, solar keratoses, skin lesions, melanoma, pain and inflammation, muscle, joint and bone disorders, cardiovascular diseases, hyperlipidemia, peripheral circulatory disorders and diabetic and metabolic disorders; Pharmaceutical products derived from natural sources, namely, Amrubicin, Daptomycin, Galantamine, Mycophenolic acid, Nitisinone, Omegacin, Pitavastatin, Rosuvastatin, Fish oil for medical purposes, Krill oil for medical purposes, Vitamin E, Vitamin D, Vitamin C, Collagen Elastin, Lycopene, Selenium, Glucosamine and Chondroitin, Panax ginseng for medical purposes, Ginger for medical purposes, Gingko biloba for medical purposes and Resveratrol; Pharmaceutical preparations containing royal jelly for the treatment of hypertension, hyperlipidemia, inflammation, asthma, hay fever, sleep disorders, insomnia, premenstrual syndrome, stomach ulcers, menopause symptoms, skin disorders, skin nutrition, health tonic, anti-aging, boosting immune system, and hair nutrition; Oils for pharmaceutical purposes, namely, Tea tree oil, Eucalyptus oil, Clove oil, Cinnamon oil, Benzoin oil and Citronella oil all for medical purposes ]SECTION 70 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 2, 2023DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Dec 2, 2023DETHDEATH OF INTERNATIONAL REGISTRATION—
Feb 6, 2023INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Dec 7, 2022XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Dec 7, 2022XXCRGENERIC MADRID TRANSACTION CREATED—
Nov 10, 2022INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Mar 10, 2022NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Mar 10, 202271AGREGISTERED-SEC.71 ACCEPTED—
Mar 4, 2022APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Aug 9, 2021ES71TEAS SECTION 71 RECEIVED—
Sep 17, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Sep 17, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 17, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 17, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 17, 2020COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Mar 10, 2020REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Aug 7, 2015FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jul 22, 2015FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jul 22, 2015FIMPFINAL DISPOSITION PROCESSED—
Jun 10, 2015FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 10, 2015R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 13, 2015OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jan 28, 2015OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jan 28, 2015OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Dec 23, 2014NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 23, 2014PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 19, 2014GPNXNOTIFICATION PROCESSED BY IB—
Dec 3, 2014OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Dec 3, 2014OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Dec 3, 2014NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 18, 2014PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Nov 10, 2014CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 10, 2014XAECEXAMINER'S AMENDMENT ENTERED—
Nov 10, 2014GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Nov 10, 2014GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 10, 2014CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 7, 2014ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Oct 2, 2014PBTQWITHDRAWN FROM PUB OTQR REQUEST—
Sep 22, 2014PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Sep 19, 2014CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 12, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 12, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 12, 2014ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Aug 28, 2014GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Aug 28, 2014GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 28, 2014CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 14, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 14, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 8, 2014ALIEASSIGNED TO LIE—
Aug 6, 2014TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 25, 2014GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 25, 2014GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 25, 2014CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 18, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 18, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 18, 2014TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 30, 2013RFNTREFUSAL PROCESSED BY IB—
Sep 6, 2013RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Sep 6, 2013RFRRREFUSAL PROCESSED BY MPU—
Sep 6, 2013RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Sep 5, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 30, 2013DOCKASSIGNED TO EXAMINER—
Aug 27, 2013MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 23, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 22, 2013REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance